NF-κB expression and outcomes in solid tumors: A systematic review and meta-analysis

Medicine (United States)

Volumn 94, Issue 40, 2015, Pages

  Wu, Dang ^a,b   Wu, Pin ^a,b   Zhao, Lufeng ^a   Huang, Lijian ^a   Zhang, Zhigang ^a,b   Zhao, Shuai ^a,b   Huang, Jian ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Cancer Institute (A Key Laboratory for Cancer Prevention and Intervention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR MARKER;

BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CELLULAR DISTRIBUTION; COLORECTAL CANCER; DISEASE FREE SURVIVAL; ESOPHAGUS CARCINOMA; GALLBLADDER CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LYMPH NODE METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; NASOPHARYNX CARCINOMA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECTUM CANCER; REVIEW; SOLID TUMOR; STOMACH CANCER; SYSTEMATIC REVIEW; TISSUE DISTRIBUTION; TRANSITIONAL CELL CARCINOMA; BIOSYNTHESIS; CARCINOMA; FEMALE; MALE; META ANALYSIS; METABOLISM; ODDS RATIO; PROGNOSIS; SURVIVAL ANALYSIS;

BIOMARKERS, TUMOR; CARCINOMA; FEMALE; HUMANS; MALE; NF-KAPPA B; ODDS RATIO; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84944057765     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001687     Document Type: Review

References (69)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
2. Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14:736-746.
3. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol. 2011;12:715-723.
4. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21:11-19.
5. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell. 1986;47:921-928.
6. Nabel GJ, Verma IM. Proposed NF-kappa B/I kappa B family nomenclature. Genes Dev. 1993;7:2063.
7. Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301-310.
8. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell. 2002;109(Suppl):S81-S96.
9. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002;3:221-227.
10. Papa S, Bubici C, Zazzeroni F, et al. The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ. 2006;13: 712-729.
11. Nolan GP, Ghosh S, Liou HC, et al. DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide. Cell. 1991;64:961-969.
12. Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861-1874.
13. Yu HG, Yu LL, Yang Y, et al. Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology. 2003;65:37-45.
14. Lee BL, Lee HS, Jung J, et al. Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. Clin Cancer Res. 2005;11:2518-2525.
15. Izzo JG, Correa AM, Wu TT, et al. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther. 2006;5:2844-2850.
16. Shukla S, Maclennan GT, Marengo SR, et al. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate. 2005;64:224-239.
17. Oya M, Ohtsubo M, Takayanagi A, et al. Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene. 2001;20:3888-3896.
18. Annunziata CM, Stavnes HT, Kleinberg L, et al. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010;116:3276-3284.
19. Li J, Jia H, Xie L, et al. Association of constitutive nuclear factor-kappaB activation with aggressive aspects and poor prognosis in cervical cancer. Int J Gynecol Cancer. 2009;19:1421-1426.
20. Baby J, Pickering BF, Vashisht Gopal YN, et al. Constitutive and inducible nuclear factor-kappaB in immortalized normal human bronchial epithelial and non-small cell lung cancer cell lines. Cancer Lett. 2007;255:85-94.
21. Jackson-Bernitsas DG, Ichikawa H, Takada Y, et al. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene. 2007;26:1385-1397.
22. Pacifico F, Mauro C, Barone C, et al. Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem. 2004;279:54610-54619.
23. Chaturvedi MM, Sung B, Yadav VR, et al. NF-kappaB addiction and its role in cancer: 'one size does not fit all'. Oncogene. 2011;30:1615-1630.
24. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.
25. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603-605.
26. Deeks JJHJ, Altman DG. Analysing and presenting results. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 425 Chichester. UK: John Wiley & Sons; 2006.
27. Berardi R, Maccaroni E, Mandolesi A, et al. Nuclear factor-kappaB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. Dig Liver Dis. 2012;44:617-622.
28. Chu D, Zhou Y, Zhang Z, et al. Notch1 expression, which is related to p65 Status, is an independent predictor of prognosis in colorectal cancer. Clin Cancer Res. 2011;17:5686-5694.
29. Kwon HC, Kim SH, Oh SY, et al. Clinicopathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancer. Cancer Sci. 2010;101:1557-1561.
30. Lewander A, Gao J, Carstensen J, et al. NF-kappaB p65 phosphory-lated at serine-536 is an independent prognostic factor in Swedish colorectal cancer patients. Int J Colorectal Dis. 2012;27:447-452.
31. Lin G, Tang Z, Ye YB, et al. NF-kappaB activity is downregulated by KRAS knockdown in SW620 cells via the RAS-ERK-IkappaBal-pha pathway. Oncol Rep. 2012;27:1527-1534.
32. O'Neil BH, Funkhouser WK, Calvo BF, et al. Nuclear factor kappa-light chain-enhancer of activated B cells is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiotheraphy. Int J Radiat Oncol Biol Phys. 2011;80:705-711.
33. Pancione M, Forte N, Sabatino L, et al. Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. Hum Pathol. 2009;40:714-725.
34. Voboril R, Voborilova J, Rychterova V, et al. Dissociated invasively growing cancer cells with NF-kappaB/p65 positivity after radiotherapy: a new marker for worse clinical outcome in rectal cancer? Preliminary data. Clin Exp Metastasis. 2008;25:491-496.
35. Abdel-Latif MM, O'Riordan J, Windle HJ, et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiother-apy. Ann Surg. 2004;239:491-500.
36. Hatata T, Higaki K, Tatebe S, et al. Immunohistochemical study of nuclear factor-kappaB expression in esophageal squamous cell carcinoma: prognostic significance and sensitivity to treatment with 5-FU. Dis Esophagus. 2012;25:716-722.
37. Izzo JG, Malhotra U, Wu TT, et al. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006;24:748-754.
38. Izzo JG, Malhotra U, Wu TT, et al. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev. 2007;16:1200-1205.
39. Kwon HC, Kim SH, Oh SY, et al. Clinicopathologic significance of expression of nuclear factor-kappaB RelA and its target gene products in gastric cancer patients. World J Gastroenterol. 2012;18:4744-4750.
40. Levidou G, Korkolopoulou P, Nikiteas N, et al. Expression of nuclear factor kappaB in human gastric carcinoma: relationship with I kappaB a and prognostic significance. Virchows Arch. 2007;450:519-527.
41. Park KW, Kim SJ, Oh SY. Clinicopathologic significance of nuclear factor-kappaB and vascular endothelial growth factor expression in advanced gastric cancer patients. Oncol Res Treat. 2014;37:183-190.
42. Yamanaka N, Sasaki N, Tasaki A, et al. Nuclear factor-kappaB p65 is a prognostic indicator in gastric carcinoma. Anticancer Res. 2004;24:1071-1075.
43. Darb-Esfahani S, Sinn BV, Weichert W, et al. Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma. Histopathology. 2010;56:727-739.
44. Guo RX, Qiao YH, Zhou Y, et al. Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int. 2008;58:749-756.
45. Kleinberg L, Dong HP, Holth A, et al. Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum Pathol. 2009;40:795-806.
46. Yang G, Xiao X, Rosen DG, et al. The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer. Clin Cancer Res. 2011;17:2181-2194.
47. Jin X, Wang Z, Qiu L, et al. Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer. Cancer Sci. 2008;99:582-589.
48. Nair VS, Gevaert O, Davidzon G, et al. NF-kappaB protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: a radiogenomics validation study to understand tumor metabolism. Lung Cancer. 2014;83:189-196.
49. Zhang D, Jin X, Wang F, et al. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer. Ann Surg Oncol. 2007;14:3581-3592.
50. Zhang Z, Ma J, Li N, et al. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer. Ann Thorac Surg. 2006;82:243-248.
51. Wu Z, Peng X, Li J, et al. Constitutive activation of nuclear factor kappaB contributes to cystic fibrosis transmembrane conductance regulator expression and promotes human cervical cancer progression and poor prognosis. Int J Gynecol Cancer. 2013;23:906-915.
52. Huang C, Huang K, Wang C, et al. Overexpression of mitogen-activated protein kinase kinase 4 and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Oncol Rep. 2009;22:89-95.
53. Jiang LZ, Wang P, Deng B, et al. Overexpression of Forkhead Box M1 transcription factor and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Hum Pathol. 2011;42:1185-1193.
54. Sun W, Guo MM, Han P, et al. Id-1 and the p65 subunit of NF-kappaB promote migration of nasopharyngeal carcinoma cells and are correlated with poor prognosis. Carcinogenesis. 2012;33:810-817.
55. Zhang Y, Lang JY, Liu L, et al. Association of nuclear factor kappaB expression with a poor outcome in nasopharyngeal carcinoma. Med Oncol. 2011;28:1338-1342.
56. Zhang J, Peng B, Chen X. Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res. 2005;11:7334-7343.
57. Korkolopoulou P, Levidou G, Saetta AA, et al. Expression of nuclear factor-kappaB in human astrocytomas: relation to pI kappa Ba, vascular endothelial growth factor, Cox-2, microvas-cular characteristics, and survival. Hum Pathol. 2008;39: 1143-1152.
58. Wu W, Pan C, Yu H, et al. Heparanase expression in gallbladder carcinoma and its correlation to prognosis. J Gastroenterol Hepatol. 2008;23:491-497.
59. Balermpas P, Michel Y, Wagenblast J, et al. Nuclear NF-kappaB expression correlates with outcome among patients with head and neck squamous cell carcinoma treated with primary chemor-adiation therapy. Int J Radiat Oncol Biol Phys. 2013;86: 785-790.
60. Zhou Q, Gong Y, Huang F, et al. Expression levels and significance of nuclear factor-kappaB and epidermal growth factor receptor in hepatolithiasis associated with intrahepatic cholangiocarcinoma. Dig Surg. 2013;30:309-316.
61. Nariai Y, Mishima K, Yoshimura Y, et al. FAP-1 and NF-kappaB expressions in oral squamous cell carcinoma as potential markers for chemo-radio sensitivity and prognosis. Int J Oral Maxillofac Surg. 2011;40:419-426.
62. Okera M, Bae K, Bernstein E, et al. Evaluation of nuclear factor kappaB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU Int. 2011;108:E51-E58.
63. Yeh HC, Huang CH, Yang SF, et al. Nuclear factor-kappaB activation predicts an unfavourable outcome in human upper urinary tract urothelial carcinoma. BJU Int. 2010;106:1223-1229.
64. Weichert W, Boehm M, Gekeler V, et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer. 2007;97:523-530.
65. Yoon SO, Kim BH, Lee HS, et al. Differential protein immunoex-pression profiles in appendiceal mucinous neoplasms: a special reference to classification and predictive factors. Mod Pathol. 2009;22:1102-1112.
66. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev. 2012;246:379-400.
67. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649-683.
68. Miyamoto S, Chiao PJ, Verma IM. Enhanced I kappa B alpha degradation is responsible for constitutive NF-kappa B activity in mature murine B-cell lines. Mol Cell Biol. 1994;14:3276-3282.
69. Tam WF, Lee LH, Davis L, et al. Cytoplasmic sequestration of rel proteins by IkappaBalpha requires CRM1-dependent nuclear export. Mol Cell Biol. 2000;20:2269-2284.